News Network


Dissecting Perioperative Immunotherapy Approaches in Early-Stage NSCLC

July 17th 2025

Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss evolving perioperative immunotherapy approaches in early-stage non–small cell lung cancer.

HAI Therapy: Clinical Value and Multidisciplinary Approach.

July 14th 2025

Experts at Ochsner MD Anderson Cancer Center review modern HAI therapy, share integration best practices, and discuss the role of the multidisciplinary care team.

Sponsored Content by Intera Oncology.

Advances in RAS Inhibition in Pancreatic Ductal Adenocarcinoma

June 26th 2025

Mike J. Pishvaian, MD, PhD, and Martin Dietrich, MD, PhD, explore emerging approaches to RAS inhibition in pancreatic ductal adenocarcinoma.

Emerging Data and Treatment Trends in Paroxysmal Nocturnal Hemoglobinuria After EHA 2025

June 24th 2025

Austin Kulasekararaj, MBBS, MD, MRCP, FRCPath, and David Dingli, MD, PhD, on updates in paroxysmal nocturnal hemoglobinuria.

The Evolving Role of CAR T-Cell Therapy in Acute Lymphoblastic Leukemia

June 24th 2025

Bijal Shah, MD, MS, and Jae Park, MD, deliver the key data and insights for CAR T-cell therapy in acute lymphoblastic leukemia.

Key Data Updates and Treatment Trends in Ovarian Cancer From ASCO 2025

June 19th 2025

Tara Berman, MD, MS, and Gottfried E. Konecny, MD, discuss updates in ADCs and more in ovarian cancer from ASCO 2025.

Dissecting Pivotal Research in Lower-Risk MDS From ASCO 2025

June 19th 2025

Guillermo Garcia-Manero, MD, details key updates in lower-risk myelodysplastic syndrome around the 2025 ASCO Annual Meeting.

On the Clock With MedNews Week: ASCO 2025

May 31st 2025

On the Clock is a dynamic video series from Med News Week and OncLive, bringing you rapid-fire insights from top oncology experts at the 2025 ASCO Annual Meeting.

The Evolution of TKIs in ROS1+ NSCLC

May 30th 2025

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, discuss treatment trends and emerging data in ROS1-positive non–small cell lung cancer.

Exploring the Management of Pediatric Relapsed/Refractory Acute Leukemia

May 21st 2025

Lia Gore, MD, and Sarah K. Tasian, MD, discuss updates in the management of pediatric relapsed/refractory acute leukemia.

Evolving Treatment Approaches After Checkpoint Inhibition in Advanced Melanoma

May 14th 2025

Michael A. Postow, MD, and Chenyang Zhan, MD, PhD, discuss novel treatment approaches in advanced melanoma after checkpoint inhibition.

The Evolving Role of ctDNA Testing in Colorectal Cancer

April 30th 2025

Scott Kopetz, MD, PhD, FACP, and Mark A. Lewis, MD, discuss the evolving role of ctDNA in the management of colorectal cancer.

Expanding on Treatment Trends in Platinum-Resistant Ovarian Cancer

March 31st 2025

Bhavana Pothuri, MD, and Tiffany Redfern, MD, FACOG, break down the latest data trends in platinum-resistant ovarian cancer.

Diving into Data Trends and Ongoing Research in Advanced Endometrial Cancer

March 26th 2025

Christian Marth, MD, PhD, and John Chan, MD, discuss the latest data trends in advanced endometrial cancer.

Delving into Updates in Metastatic Hormone-Sensitive Prostate Cancer

March 12th 2025

Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss updates in the metastatic hormone-sensistive prostate cancer realm.

The Evolving Treatment Paradigm for Platinum-Resistant Ovarian Cancer

February 6th 2025

Floortje J Backes, MD, discusses evolving treatment considerations for platinum-resistant ovarian cancer.

Developments in Acute Lymphoblastic Leukemia Following ASH 2024

January 8th 2025

George Yaghmour, MD, and Rachel Elizabeth Rau, MD, discuss updates in acute lymphoblastic leukemia following ASH 2024.

Developments in the Management of Myelofibrosis After ASH 2024

December 20th 2024

Sangeetha Venugopal, MD, MS, discusses treatment trends and emerging data in the management of myelofibrosis.

Highlighting Key Follicular Lymphoma Data Following ASH 2024

December 20th 2024

Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss key updates in the follicular lymphoma field following the 2024 ASH Annual Meeting

Treatment Trends and Key Data Emerging in Myelodysplastic Syndrome After ASH 2024

December 18th 2024

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, highlight treatment trends and key data emerging in the field of myelodysplastic syndromes.

x